WO2006135382A3 - Enzymatic activities in chemokine-mediated inflammation - Google Patents

Enzymatic activities in chemokine-mediated inflammation Download PDF

Info

Publication number
WO2006135382A3
WO2006135382A3 PCT/US2005/027728 US2005027728W WO2006135382A3 WO 2006135382 A3 WO2006135382 A3 WO 2006135382A3 US 2005027728 W US2005027728 W US 2005027728W WO 2006135382 A3 WO2006135382 A3 WO 2006135382A3
Authority
WO
WIPO (PCT)
Prior art keywords
fprl1
chemokine
ccr1
enzymatic activities
mediated inflammation
Prior art date
Application number
PCT/US2005/027728
Other languages
French (fr)
Other versions
WO2006135382A2 (en
Inventor
Robert D Berahovich
Zhenhua Miao
Brett Premack
Thomas J Schall
Original Assignee
Chemocentryx Inc
Robert D Berahovich
Zhenhua Miao
Brett Premack
Thomas J Schall
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc, Robert D Berahovich, Zhenhua Miao, Brett Premack, Thomas J Schall filed Critical Chemocentryx Inc
Publication of WO2006135382A2 publication Critical patent/WO2006135382A2/en
Publication of WO2006135382A3 publication Critical patent/WO2006135382A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

Truncated chemokines lacking an N-terminal region that activate CCR1 and/or FPRL1 and compositions containing the truncated chemokines are provided. Methods of identifying agents that modulate CCR1 and/or FPRL1 activity either by modulating the production of the truncated chemokines or the ability of the truncated chemokines to activate CCR1 and/or FPRL1 are also disclosed. Methods using the truncated chemokines to inhibit or activate CCR1 and/or FPRL1 mediated biological activities are also disclosed.
PCT/US2005/027728 2004-08-04 2005-08-04 Enzymatic activities in chemokine-mediated inflammation WO2006135382A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59895904P 2004-08-04 2004-08-04
US60/598,959 2004-08-04

Publications (2)

Publication Number Publication Date
WO2006135382A2 WO2006135382A2 (en) 2006-12-21
WO2006135382A3 true WO2006135382A3 (en) 2007-12-27

Family

ID=37532726

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/027728 WO2006135382A2 (en) 2004-08-04 2005-08-04 Enzymatic activities in chemokine-mediated inflammation

Country Status (2)

Country Link
US (1) US7572600B2 (en)
WO (1) WO2006135382A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8221995B2 (en) 2007-03-23 2012-07-17 Seok-Won Lee Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050832A1 (en) * 2004-12-23 2008-02-28 Buechler Kenneth F Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
WO2007041623A2 (en) * 2005-10-03 2007-04-12 Biosite Incorporated Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US20090004755A1 (en) * 2007-03-23 2009-01-01 Biosite, Incorporated Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
SE540775C2 (en) * 2016-03-21 2018-11-06 Microfluidic device for culturing cells
CN109679981A (en) * 2019-02-21 2019-04-26 武汉大学 A kind of formyl peptides directed evolution bacteriophage and the preparation method and application thereof
WO2023212095A1 (en) * 2022-04-27 2023-11-02 The Regents Of The University Of California Molecules that enhance extracellular vesicle release

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
LU86084A1 (en) 1985-09-20 1987-04-02 Faco Sa ELECTRIC MASSAGE APPARATUS
US4800882A (en) 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4886062A (en) 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
JP2647119B2 (en) * 1988-03-04 1997-08-27 株式会社デンソー Travel control device for vehicles
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69032284T2 (en) 1989-03-21 1998-10-08 Vical Inc EXPRESSION OF EXOGENOUS POLYNUCLEOTIDE SEQUENCES IN VERTEBLE
WO1990013332A1 (en) 1989-05-11 1990-11-15 Cedars-Sinai Medical Center Stent with sustained drug delivery
US5284746A (en) 1990-02-08 1994-02-08 Zymogenetics, Inc. Methods of producing hybrid G protein-coupled receptors
DE69110787T2 (en) 1990-02-28 1996-04-04 Medtronic Inc INTRALUMINAL PROSTHESIS WITH ACTIVE ELEMENTATION.
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
EP0600866B1 (en) 1990-06-01 1997-12-03 Chiron Corporation Compositions and methods for identifying biologically active molecules
US5124350A (en) 1990-06-28 1992-06-23 G. D. Searle & Co. Leukotriene b4 antagonists
GB2276169A (en) 1990-07-05 1994-09-21 Celltech Ltd Antibodies specific for carcinoembryonic antigen
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
KR100272077B1 (en) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 Transgenic non-human animals capable of producing heterologous antibodies
TW304957B (en) 1991-06-18 1997-05-11 Lilly Co Eli
AU669489B2 (en) 1991-09-18 1996-06-13 Affymax Technologies N.V. Method of synthesizing diverse collections of oligomers
DE69333814T2 (en) 1992-03-11 2006-02-02 Powderject Vaccines, Inc., Madison GENETIC VACCINE AGAINST IMMUNE WEAKNESS VIRUS
CA2134773A1 (en) 1992-06-04 1993-12-09 Robert J. Debs Methods and compositions for in vivo gene therapy
EP0665897B1 (en) 1992-10-01 2003-07-09 The Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
US5419760A (en) 1993-01-08 1995-05-30 Pdt Systems, Inc. Medicament dispensing stent for prevention of restenosis of a blood vessel
US5429634A (en) 1993-09-09 1995-07-04 Pdt Systems Biogenic implant for drug delivery and method
US5514555A (en) 1993-03-12 1996-05-07 Center For Blood Research, Inc. Assays and therapeutic methods based on lymphocyte chemoattractants
WO1995012608A1 (en) 1993-11-02 1995-05-11 Affymax Technologies N.V. Synthesizing and screening molecular diversity
JPH10500112A (en) 1994-05-06 1998-01-06 ファーマコピーア，インコーポレイテッド Combination dihydrobenzopyran library
US5663046A (en) 1994-06-22 1997-09-02 Pharmacopeia, Inc. Synthesis of combinatorial libraries
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5563762A (en) 1994-11-28 1996-10-08 Northern Telecom Limited Capacitor for an integrated circuit and method of formation thereof, and a method of adding on-chip capacitors to an integrated circuit
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
EP0916668A4 (en) 1996-07-29 2000-08-16 Banyu Pharma Co Ltd Chemokine receptor antagonists
US5736035A (en) * 1996-08-19 1998-04-07 Nurse, Jr.; Harry L. Outlet filter for waste water treatment tank
US6329510B1 (en) * 1999-01-29 2001-12-11 Millennium Pharmaceuticals, Inc. Anti-CCR1 antibodies and methods of use therefor
US6723538B2 (en) * 1999-03-11 2004-04-20 Micromet Ag Bispecific antibody and chemokine receptor constructs
US20030096260A1 (en) * 2001-10-09 2003-05-22 Zhenhua Miao Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof
US6770729B2 (en) 2002-09-30 2004-08-03 Medtronic Minimed, Inc. Polymer compositions containing bioactive agents and methods for their use

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BERAHOVICH ROBERT D ET AL: "Proteolytic activation of alternative CCR1 ligands in inflammation", JOURNAL OF IMMUNOLOGY, vol. 174, no. 11, June 2005 (2005-06-01), pages 7341 - 7351, XP002435923, ISSN: 0022-1767 *
DETHEUX M ET AL: "Natural proteolytic processing of hemofiltrate CC chemokine 1 generates a potent CC chemokine receptor (CCR)1 and CCR5 agonist with anti-HIV properties", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 192, no. 10, 20 November 2000 (2000-11-20), pages 1501 - 1508, XP002241991, ISSN: 0022-1007 *
ESCHER S E ET AL: "Functional analysis of chemically synthesized derivatives of the human CC chemokine CCL15/HCC-2, a high affinity CCR1 ligand.", JOURNAL OF PEPTIDE RESEARCH, vol. 63, no. 1, January 2004 (2004-01-01), pages 36 - 47, XP002435922, ISSN: 1397-002X *
NAYA A ET AL: "DESIGN, SYNTHESIS, AND DISCOVETY OF A NOVEL CCR1 ANTAGONIST", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 44, no. 9, 2001, pages 1429 - 1435, XP002946303, ISSN: 0022-2623 *
VAKILI J ET AL: "Urokinase plasminogen activator and plasmin efficiently convert hemofiltrate CC chemokine 1 into its active.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 SEP 2001, vol. 167, no. 6, 15 September 2001 (2001-09-15), pages 3406 - 3413, XP002435921, ISSN: 0022-1767 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8221995B2 (en) 2007-03-23 2012-07-17 Seok-Won Lee Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes

Also Published As

Publication number Publication date
US7572600B2 (en) 2009-08-11
WO2006135382A2 (en) 2006-12-21
US20060063223A1 (en) 2006-03-23

Similar Documents

Publication Publication Date Title
WO2006135382A3 (en) Enzymatic activities in chemokine-mediated inflammation
WO2006124892A3 (en) Modulators of alpha-synuclein toxicity
WO2008063888A3 (en) Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2006137934A3 (en) Purposeful movement of human migratory cells away from an agent source
WO2006034235A3 (en) Substituted quinoline and quinazoline inhibitors of quinone reductase 2
WO2005021558A3 (en) Proteasome inhibitors and methods of using the same
EP2662088A3 (en) Anti-connexin compounds and uses thereof
WO2005118544A3 (en) Cycloalkyl substituted pyrimidinediamine compounds and their uses
EP2364705A3 (en) Modulators of muscarinic receptors
TW200519110A (en) Substituted tetrahydro-1H-pyrazolo [3, 4-c] pyridines, compositions comprising them, and use
WO2007062243A3 (en) Serum-free expansion of cells in culture
WO2007097993A3 (en) Media conditioned by human embryonic stem cells or other progenitor cells and uses therefor
WO2005117968A3 (en) Compositions and methods comprising an egfl7 antagonist for modulating vascular development
WO2007067828A3 (en) Glp-2 mimetibodies, polypeptides, compositions, methods and uses
WO2007056352A3 (en) Compositions and methods for controlling tissue factor signaling specificity
WO2007053815A3 (en) Compositions and methods for organic juice based skin care products
WO2005077122A3 (en) Compounds and compositions as lxr modulators
MX2009006812A (en) Modulators of c3a receptor and methods of use thereof.
WO2006114105A8 (en) Use of modified factor vii for treating bleeding
WO2006076240A3 (en) Compositions, products and methods for controlling weight in a mammal
WO2008036421A3 (en) Reishi-mediated enhancement of human tissue progenitor cell adhesion and differentiation
WO2006017456A3 (en) Chymopapain isoenzymes, compositions, and uses thereof
MXPA05013226A (en) Substituted piperidine carbamates for use as inhibitors of hormone sensitive lipase.
WO2005077124A3 (en) Compounds and compositions as lxr modulators
WO2009017719A3 (en) Modulators of ccr9 receptor and methods of use thereof

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase